This article is more than 5 years old. Information may no longer be current.

Travoprost intraocular implant lowers IOP

Issue: December 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN ANTONIO – IDose-slow and iDose-fast from Glaukos were shown in a phase 2 prospective, randomized, clinical trial to lower IOP 32% and 33% at 12 weeks and maintain that level out to 12 months, according to Mitch Ibach, OD, here at the American Academy of Optometry meeting.

“The iDose will give us a way to pharmacologically manage patients with glaucoma, increasing patient compliance and decreasing adverse ocular events,” he said.

Disclosure: Ibach reports he is a consultant to and lecturer for Glaukos.